`
`Market News
`
`Open New Account
`
`Account Types
`
`Funding & Transfers
`
`Keywords or Stocks
`
`Client Login
`
`Service
`
`Tools & Platforms
`
`Investment Products
`
`Pricing
`
`Retirement
`
`Education
`
`Research
`
`Markets: News
`
`Markets
`
`News
`
`Indices
`
`Sectors and
`Industries
`
`Calendar
`
`Analyst Reports
`
`Stocks
`
`Options
`
`Mutual Funds
`
`ETFs
`
`Bonds & CDs
`
`Screeners
`
`Ideas
`
`Investor Movement
`Index (IMX)
`
`At This Moment
`
`
`
`Search News
`
`By symbol
`
`Enter symbol...
`
`Search
`
`Back to News Overview
`
`NPS Pharmaceuticals (NPSP) $32.25 down $0.35...
`6/3/14 12:50 PM ET (S&P Capital IQ)
`
`STRATEGY: Look at the July 31 covered call. For each 100 shares of NPS Pharmaceuticals (NPSP)
`stock you buy, sell one July 31 covered call option for a $28.95 ($32.25 - $3.30) debit or better. That's
`potentially a 7.1% assigned return. IK -> COMMENT: The technicals for NPSP are neutral with an
`upward trend. The stock has support around $22.60 and resistance near $39.70. The company is next
`expected to report earnings in early August. S&P Capital IQ ranks this stock as 5 STARS (out of five) -
`strong buy. RISK: The stock has to drop 10.2% to threaten the break even point. This trade rates 3 keys
`out of 5 - moderate relative risk. S&P RESEARCH NOTES: S&P CAPITAL IQ REITERATES STRONG
`BUY OPINION ON SHARES OF NPS PHARMACEUTICALS. According to an unconfirmed report in the
`Times of London, Shire Plc (SHPG) is preparing a bid for NPSP. According to the report, SHP's initial
`approach to NPSP was turned down, but SHP has retained an investment banking firm and secured a
`$5B credit facility to fund a deal. We think the combination makes strategic sense as both firms focus
`on rare diseases. In January, SHP completed the $4.2B acquisition of specialty pharma firm
`ViroPharma. But we note SHP has also been subject to recent takeover rumors themselves. We keep
`our target price at $42.
`
`Back to News Overview
`
`Latest Headlines
`
`Willis Tower Watson to replace Fossil
`Group on S&P 500
`12/28/2015 (MarketWatch)
`Pep Boys shares rally as Icahn increases
`takeover bid
`12/28/2015 (MarketWatch)
`Wall Street's forecast for 2016: Worse than
`2015's
`12/28/2015 (MarketWatch)
`More recent headlines...
`
`More Options headlines
`
`More Options headlines...
`
` Copyright ©2015. All rights reserved.
`,
`News provided by
`Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information
`included in such material.
`3rd Party Research Disclosure /public-19:29:42
`
`CLIENT LOG-IN
`
`ABOUT US
`
`CONTACT US
`
`SECURITY
`
`THE TICKER TAPE
`
`FORM LIBRARY
`
`FIND A BRANCH
`
`MOBILE SITE
`
`FEEDBACK
`
`Stay connected with us:
`
`DOW 17,528.27
`−23.9 (0.14%)
`
`NASDAQ 5,040.99
`−7.5 (0.15%)
`
`S&P 500 2,056.5
`−4.49 (0.22%)
`
`12/28/15 1:34PM PT
`
`Trade commission-free for 60 days
`plus get up to $600 Offer Details
`
`Open an account
`
`Careers Search Jobs Minimum Requirements Disclosures Privacy Financial Statement Newsroom Site Map
`TD Ameritrade Institutional International TDW URLs TD Ameritrade Holding Corp.
`
`AdChoices
`
`TD Ameritrade, Inc., member FINRA / SIPC. This is not an offer or solicitation in any jurisdiction where we are not authorized to do business. TD Ameritrade is a trademark jointly owned by TD Ameritrade IP
`Company, Inc. and The TorontoDominion Bank. © 2015 TD Ameritrade IP Company, Inc. All rights reserved. Used with permission.
`
`https://research.tdameritrade.com/grid/public/markets/news/story.asp?docKey=1214ALERT5_632014&category=Options
`
`1/1
`
`Go
`
`Page 1